Next Health Lincoln Park
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Cryotherapy
Chicago, IL
Chicago has a Midwestern professional demographic and strict Illinois compounding oversight, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across River North, the Gold Coast, Lincoln Park, and the North Shore suburbs range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Northwestern Memorial, Rush, and the University of Chicago network. The scene here skews toward physician-led functional medicine practices that have added peptides alongside HRT and IV. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Chicago clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, limiting 503A pharmacy sourcing. Section 503A covers traditional compounding pharmacies; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
The Illinois Department of Financial and Professional Regulation (IDFPR) oversees pharmacy inspections and compounding compliance. Non-resident pharmacies must hold a current Illinois non-resident permit. The IDFPR has taken action against pharmacies for sterile compounding deficiencies.